Aldeyra Therapeutics Inc
Follow $ALDX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ALDX by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredsnapshot unavailable for ALDX. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ALDX moving today?
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ALDX overview
Related filings and maps
Congress activity in ALDX
No receipt-qualified Congressional disclosure is present for ALDX in the cached public ledger.
ALDX contract awards, year to date.
Public federal awards linked to this ticker.
ALDX lobbying filings, year to date.
Registered lobbying filings matched to Aldeyra Therapeutics Inc.